AVERSA™ Transdermal Technology
Indication
Chronic Pain
Pre-Clinical
Phase I
NDA Filing
AVERSA™ Transdermal Technology
Indication
Chronic Pain
Pre-Clinical
Phase I
NDA Filing
AVERSA™ Transdermal Technology
Indication
Attention Deficit Hyperactivity Disorder (ADHD)
Pre-Clinical
Phase I
NDA Filing
Novel Transdermal
Indication
Type 2 Diabetes
Pre-Clinical
Phase I
Phase II
Phase III
NDA Filing
Novel Transdermal
Indication
Infertility
Pre-Clinical
Phase I
Phase II
Phase III
NDA Filing
Aversa™ abuse deterrent technology can be incorporated into any transdermal patch that has a risk of abuse.